Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 8151–8200 of 76387
On March 28, 2025, Mr. Christopher Egan provided notice of his resignation from the Board of Directors (the “Board”) of CCC Intelligent Solutions Holdings Inc. (the “Company”), effective immediately.
On March 28, 2025, Charles R. Wells, IV, the Company’s Executive Vice President and Chief Operating Officer, informed the Company that he will be departing for a chief executive officer role at a privately held company.
On March 20, 2025, Kent Wilson and Ian Kantrowitz submitted their resignations as members of the Board of Directors (the “Board”), serving in only an advisory capacity for the wind down of the Company, as needed.
On March 20, 2025, Kent Wilson and Ian Kantrowitz submitted their resignations as members of the Board of Directors (the “Board”), serving in only an advisory capacity for the wind down of the Company, as needed.
On March 31, 2025, TechPrecision Corporation (the “ Company ”) announced that the Board of Directors (the “ Board ”) of the Company appointed Phillip E. Podgorski to serve as the Chief Financial Officer of the Company, effective March 31, 2025
Barbara M. Lilley stepped down as the Company’s Interim Chief Financial Officer and will retain her position as Controller of Ranor, Inc., a wholly owned subsidiary of the Company, effective on the Transition Date.
On March 31, 2025, effective upon the completion of the Distribution and pursuant to the employment transition agreement previously filed by the Company on January 13, 2025 with the Securities Exchange Commission as Exhibit 10.1 to the Current Report on Form 8-K dated January 13, 2025, Joseph Levin ceased to serve as Chief Executive Officer of the Company and as a member of the board of directors of the Company.
On March 31, 2025, effective upon the completion of the Distribution and pursuant to the employment transition agreement previously filed by the Company on January 13, 2025 with the Securities Exchange Commission as Exhibit 10.1 to the Current Report on Form 8-K dated January 13, 2025, Joseph Levin ceased to serve as Chief Executive Officer of the Company and as a member of the board of directors of the Company.
each of Christopher Halpin, Kendall F. Handler and Mark Stein notified Angi of his or her respective resignation from the Angi board of directors, effective as of March 31, 2025.
each of Christopher Halpin, Kendall F. Handler and Mark Stein notified Angi of his or her respective resignation from the Angi board of directors, effective as of March 31, 2025.
each of Christopher Halpin, Kendall F. Handler and Mark Stein notified Angi of his or her respective resignation from the Angi board of directors, effective as of March 31, 2025.
Neil Boehm, Kevin Nash and Scott Ryan joined Steven Downing as the directors of the Surviving Corporation
At the Effective Time, each of Ari M. Shalam, Patrick M. Lavelle, Beat Kahli, John J. Shalam, Denise Waund Gibson and John Adamovich, Jr. ceased to serve as directors of the Company
At the Effective Time, each of Ari M. Shalam, Patrick M. Lavelle, Beat Kahli, John J. Shalam, Denise Waund Gibson and John Adamovich, Jr. ceased to serve as directors of the Company
At the Effective Time, each of Ari M. Shalam, Patrick M. Lavelle, Beat Kahli, John J. Shalam, Denise Waund Gibson and John Adamovich, Jr. ceased to serve as directors of the Company
Neil Boehm, Kevin Nash and Scott Ryan joined Steven Downing as the directors of the Surviving Corporation
At the Effective Time, each of Ari M. Shalam, Patrick M. Lavelle, Beat Kahli, John J. Shalam, Denise Waund Gibson and John Adamovich, Jr. ceased to serve as directors of the Company
Neil Boehm, Kevin Nash and Scott Ryan joined Steven Downing as the directors of the Surviving Corporation
At the Effective Time, each of Ari M. Shalam, Patrick M. Lavelle, Beat Kahli, John J. Shalam, Denise Waund Gibson and John Adamovich, Jr. ceased to serve as directors of the Company
At the Effective Time, each of Ari M. Shalam, Patrick M. Lavelle, Beat Kahli, John J. Shalam, Denise Waund Gibson and John Adamovich, Jr. ceased to serve as directors of the Company
As of the Effective Time, and pursuant to the terms of the Merger Agreement, Sandy Spring’s directors and executive officers ceased serving as directors and executive officers of Sandy Spring.
As of the Effective Time, and pursuant to the terms of the Merger Agreement, Sandy Spring’s directors and executive officers ceased serving as directors and executive officers of Sandy Spring.
As of the Effective Time, and pursuant to the terms of the Merger Agreement, Sandy Spring’s directors and executive officers ceased serving as directors and executive officers of Sandy Spring.
Thomas M. O’Brien stepped down as Chairman, President and Chief Executive Officer
Peggy Daitch, Tracey Dedrick, Benjamin Wineman and Eboh Okorie have resigned from their roles as directors
Christine Meredith stepped down as Chief Operating Officer
Peggy Daitch, Tracey Dedrick, Benjamin Wineman and Eboh Okorie have resigned from their roles as directors
Elizabeth M. Keogh stepped down as Chief Legal Officer and Corporate Secretary
Steven E. Gallotta has been appointed Chairman of the Board
Peggy Daitch, Tracey Dedrick, Benjamin Wineman and Eboh Okorie have resigned from their roles as directors
Karen Knott stepped down as Executive Vice President
Peggy Daitch, Tracey Dedrick, Benjamin Wineman and Eboh Okorie have resigned from their roles as directors
Eleni Willis stepped down as Chief Risk Officer
The three directors of Sandy Spring mutually agreed by the Company and Sandy Spring, each of whom previously served as a member of the board of directors of Sandy Spring immediately prior to the Merger and was appointed by the Board to fill the vacancies resulting from the increase in the size of the Board referred to above, in each case effective as of the Effective Time, are as follows: Daniel J. Schrider, Mona Abutaleb Stephenson and Mark C. Micklem (collectively, the “New Directors”).
The three directors of Sandy Spring mutually agreed by the Company and Sandy Spring, each of whom previously served as a member of the board of directors of Sandy Spring immediately prior to the Merger and was appointed by the Board to fill the vacancies resulting from the increase in the size of the Board referred to above, in each case effective as of the Effective Time, are as follows: Daniel J. Schrider, Mona Abutaleb Stephenson and Mark C. Micklem (collectively, the “New Directors”).
The three directors of Sandy Spring mutually agreed by the Company and Sandy Spring, each of whom previously served as a member of the board of directors of Sandy Spring immediately prior to the Merger and was appointed by the Board to fill the vacancies resulting from the increase in the size of the Board referred to above, in each case effective as of the Effective Time, are as follows: Daniel J. Schrider, Mona Abutaleb Stephenson and Mark C. Micklem (collectively, the “New Directors”).
On March 27, 2025, W. Thorpe McKenzie informed the Board of Directors (the “Board”) of XBiotech Inc. (the “Company”) via letter of his decision to retire from the Board, effective immediately.
On April 1, 2025, Mr. Moller was appointed Principal Accounting Officer
and Todd W. Garner, Executive Vice President of Finance and Chief Financial Officer, ceased serving in the role of Principal Accounting Officer.
Kimberly A. Lockwood, who was acting as Interim Corporate Controller, has been promoted to Senior Director of Financial Reporting.
Simon Tate notified Climb Bio, Inc. (the “Company”) of his decision to resign as a member of the Company’s board of directors
Mr. Cumbo was elected to serve with a term expiring at the Company’s 2026 annual meeting of stockholders and thereafter until his successor has been duly appointed and qualified or until his earlier death, resignation or removal.
Ms. Drapkin was elected to serve with a term expiring at the Company’s 2027 annual meeting of stockholders and thereafter until her successor has been duly appointed and qualified or until her earlier death, resignation or removal.
Adam Rosenberg notified the Company that he does not intend to seek re-election as a member of the Board when his current term ends at the Company’s 2025 annual meeting of stockholders.
Terrie Curran who resigned as President and Chief Executive Officer and as a member of the Company’s Board of Directors (the “Board”) for personal reasons, effective March 31, 2025.
Steven Basta was appointed as the Chief Executive Officer, President and as a Class I director of Phathom Pharmaceuticals, Inc. (the “Company”), replacing Terrie Curran who resigned as President and Chief Executive Officer and as a member of the Company’s Board of Directors (the “Board”) for personal reasons, effective March 31, 2025.
On March 31, 2025, Todd M. Ricketts notified the Board of Directors (the “Board”) of The Charles Schwab Corporation of his intention to retire from the Board effective October 7, 2025.
On April 1, 2025, Kohl’s Corporation (the “Company”) announced that Siobhán Mc Feeney, the Company’s Chief Technology and Digital Officer, will be departing the Company effective April 2, 2025.
On March 27, 2025, Matthew Lang, J.D. notified the Company of his resignation as Chief Business Officer and from all other offices of the Company, effective April 13, 2025.
On March 28, 2025, Ng Ah Lek resigned from his positions as an Independent Director of Graphjet Technology (the “Company”) and as a member of the Company’s Audit Committee, Renumeration Committee, and Nominating and Corporate Governance Committee.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.